



Attorney Docket No. 5108N2P1

DT07 Rec'd PCT/PTO 25 OCT 2004

PATENT

PCT
X
F

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Zhang, *et al.*

Serial No.: 10/501,690

Filed: 07/16/2004

For: Fused Tricyclic Heterocycles Useful for Treating Hyper-Proliferative Disorders

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: OCT 21 2004

Jill Durante
Jill Durante

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,

Reg. No.: 31,018

Telephone: (203) 812-2712

Date: OCT 21 2004.

William F. Gray
William F. Gray
Attorney for Applicant(s)
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516



10 Rec'd FGT/PTC 25 OCT 2004

Form PTO-449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/501,690	Art Unit	Filing Date 07/16/2004	Atty. Docket No. 5108N2P1
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s) Zhang, et al.			

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	U2	5	9	2	2	7	4	0	07/13/99				
	U3	5	6	9	1	3	5	9	11/25/97				
	U4	5	6	2	2	9	8	9	04/22/97				
	U5	5	5	6	5	4	8	8	10/15/96				
	U6	5	5	0	4	2	1	3	04/02/96				

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F2	0	5	5	1	6	6	2	21/07/93	EP				
	F3	0	7	3	1	0	9	9	11/09/96	EP				
	F4	9	8	0	2	4	4	0	22/01/98	WO				
	F5	0	0	6	9	8	4	4	23/11/00	WO				
	F6	0	0	6	9	8	4	3	23/11/00	WO				
	F7	0	0	6	9	8	4	2	23/11/00	WO				
	F8	0	0	6	9	8	4	1	23/11/00	WO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Patent Abstracts of Japan, Vol. 009, No. 205 (C-299), 22 August 1985 and JP 60 072880 A (Kaken Seiyaku KK), 24 April 1985.
R2	Hayakawa, et al., "4-Hydroxy-3-Methyl-6-Phenylbenzofuran-2-Carboxylic Acid Ethyl Ester Derivatives as Potent Anti-Tumor Agents," <i>Bioorg. Med. Chem. Lett.</i> , <u>14</u> , 455-458 (2004).
R3	Hayakawa, et al., "A Library Synthesis of 4-Hydroxy-3-Methyl-6-Phenylbenzofuran-2-Carboxylic Acid Ethyl Ester Derivatives as Anti-Tumor Agents," <i>Bioorg. Med. Chem. Lett.</i> , <u>14</u> , 4383-4387 (2004).
R4	Hayakawa, et al., "Thienopyridine and Benzofuran Derivatives as Potent Anti-Tumor Agents Possessing Different Structure-Activity Relationships," <i>Bioorg. Med. Chem. Lett.</i> , <u>14</u> , 3411-3414 (2004).

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.